BiotechTV - News

← BiotechTV - NewsNeu · 12 Min.

Oxford, UK based OMass Therapeutics announced a $310M series C today, advancing its small molecule platform, including the lead MC2 (melanocortin-2) receptor antagonist that is in phase 1

Oxford, UK based OMass Therapeutics announced a $310M series C today, advancing its small molecule platform, including the lead MC2 (melanocortin-2) receptor antagonist that is in phase 1Neu12 Min.
In Spotify hörenFunktioniert auch im Browser
11 weitere Apps

<p>CEO Ros Deegan describes the raise and the new investors that it brings into the company, and updates us on the company&#39;s pipeline progress.</p>